Flax Pond Capital LLC Takes $364,000 Position in Compass Pathways PLC Sponsored ADR $CMPS

Flax Pond Capital LLC purchased a new stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 52,816 shares of the company’s stock, valued at approximately $364,000. Flax Pond Capital LLC owned 0.06% of Compass Pathways at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Corient Private Wealth LLC raised its holdings in Compass Pathways by 3.2% in the 4th quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after acquiring an additional 1,200 shares in the last quarter. Conservest Capital Advisors Inc. raised its stake in Compass Pathways by 24.6% in the fourth quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after purchasing an additional 5,000 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in Compass Pathways during the fourth quarter worth about $38,000. Raymond James Financial Inc. lifted its position in Compass Pathways by 82.7% during the third quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after purchasing an additional 6,228 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Compass Pathways during the fourth quarter worth about $47,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on CMPS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a report on Monday, April 20th. Maxim Group increased their price objective on Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a report on Friday, May 15th. BTIG Research restated a “buy” rating and issued a $14.00 price objective on shares of Compass Pathways in a report on Wednesday, May 13th. Morgan Stanley raised their target price on Compass Pathways from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. Finally, Wolfe Research assumed coverage on Compass Pathways in a report on Friday, May 22nd. They set an “outperform” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.36.

Compass Pathways Stock Performance

NASDAQ CMPS opened at $12.53 on Friday. The company has a market cap of $1.69 billion, a P/E ratio of -3.98 and a beta of 2.50. The company has a fifty day simple moving average of $10.22 and a 200 day simple moving average of $7.84. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. Compass Pathways PLC Sponsored ADR has a 12-month low of $2.25 and a 12-month high of $14.76.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Sell-side analysts predict that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.